NWBO · Northwest Biotherapeutics Inc
$0.16
-0.01 (-6.92%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because of recurring operating losses and operating cash flow deficits, there is substantial doubt about the Company’s ability to continue as a going concern for at least one year from the date of this filing.”View the 10-Q filed May 15, 2026
Market Cap
$262.93M
Shares
1.64B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.38M
-0.3%
FY2025
Net Income
-$60.16M
+28.2%
FY2025
Gross Margin
52.78%
-47.2pp
FY2013
Operating Margin
-4347.9%
+464.6pp
FY2025
Diluted EPS
-$0.04
+42.9%
FY2025
Operating Cash Flow
-$44.76M
+21.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 | FY2002 | FY2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.5M | $1.38M | $1.38M | $1.93M | $1.68M | $1.01M | $1.29M | $2.41M | $412K | $336K | $623K | $1.74M | $1.45M | $809K | $772K | $10K | $10K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $382K | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $427K | $772K | $10K | $10K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | 52.78% | 100% | 100% | 100% | — | — | — | — | — | — | — | — | — | |
| $25.29M | $28.79M | $34.89M | $27.73M | $35.51M | $20.31M | $33.64M | $14.11M | $18.15M | $33.52M | $60.08M | $103.12M | $85.64M | $43.91M | $28.91M | $13.45M | $9.9M | — | — | — | — | — | — | — | — | — | |
| $29.71M | $32.51M | $33M | $29.71M | $33.35M | $33.4M | $54.26M | $16.28M | $22.51M | $12.46M | $10.87M | $18.33M | $16.96M | $12.38M | $15.68M | $13.34M | $5.46M | — | — | — | — | — | — | — | — | — | |
| — | $2.06M | $1.74M | $1.53M | $1.25M | $324K | $87K | $21K | $1.29M | $439K | $189K | $56K | $11K | $11K | $14K | $10K | $2000 | — | — | — | — | — | — | — | — | — | |
| -$53.5M | -$59.91M | -$66.51M | -$55.51M | -$67.18M | -$52.7M | -$86.61M | -$27.98M | -$41.48M | -$54.68M | -$79.27M | -$126.28M | -$101.14M | -$55.47M | -$43.83M | -$26.79M | -$15.35M | — | — | — | — | — | — | — | — | — | |
| — | -4347.9% | -4812.45% | -2873.08% | -3991.74% | -5243.98% | -6708.37% | -1160.95% | -10068.2% | -16273.21% | -12723.27% | -7261.87% | -6956.19% | -6857.11% | -5676.81% | -267870% | -153540% | — | — | — | — | — | — | — | — | — | |
| — | -$57.85M | -$64.76M | -$53.98M | -$65.93M | -$52.38M | -$86.52M | -$27.96M | -$40.19M | -$54.24M | -$79.08M | -$126.23M | -$101.13M | -$55.46M | -$43.81M | -$26.78M | -$15.35M | — | — | — | — | — | — | — | — | — | |
| $9.44M | $8.7M | $7.77M | $5.24M | $6.07M | $5.01M | $8.54M | $2.98M | $9.87M | $5.55M | $3.82M | $4.15M | $996K | $842K | $13.44M | $7.65M | $7.88M | — | — | — | — | — | — | — | — | — | |
| $9.08M | -$785K | -$17.27M | -$7.09M | -$37.85M | $231.83M | -$443.22M | $7.17M | $5.69M | -$18.47M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$60.7M | -$83.78M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$537K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | |
| -$43.89M | -$60.16M | -$83.78M | -$62.6M | -$105.03M | $179.13M | -$529.82M | -$20.81M | -$35.79M | -$73.14M | -$80.21M | -$114.74M | -$135.63M | -$65.79M | -$67.32M | -$32.83M | -$27.37M | -$26.95M | -$22.33M | -$21.25M | -$1.4M | -$9.94M | -$8.51M | -$5.75M | -$12.8M | -$10.94M | |
| — | -4365.89% | -6062.08% | -3240.11% | -6240.76% | 17823.48% | -41039.58% | -863.57% | -8687.86% | -21768.75% | -12875.44% | -6598.1% | -9328.34% | -8132.14% | -8720.21% | -328300% | -273680% | — | — | — | — | — | — | — | — | — | |
| -$45.27M | -$61.48M | -$85.19M | -$64.37M | -$105.03M | $179.13M | -$529.82M | -$20.81M | -$53.56M | -$74.41M | -$85.86M | -$114.74M | — | -$384.89M | -$67.32M | -$32.83M | -$27.37M | — | — | — | — | — | — | — | — | — | |
| -$47.1M | -$65.45M | -$83.69M | -$65.98M | -$102.24M | $180.63M | -$531.81M | -$20.98M | -$34.2M | -$75.59M | -$78.24M | -$114.67M | -$135.63M | -$65.98M | — | -$32.83M | -$27.47M | -$26.98M | -$22.35M | -$21.25M | — | — | — | — | — | — | |
| USD/shares | — | -$0.04 | -$0.07 | -$0.06 | -$0.10 | $0.21 | -$0.73 | -$0.04 | — | — | — | — | — | — | — | -$0.35 | -$0.41 | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$0.04 | -$0.07 | -$0.06 | -$0.10 | -$0.06 | -$0.73 | -$0.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 1.46B | 1.24B | 1.12M | 1.02M | 873.52K | 725.13K | 564.19K | 440.02M | 242.85M | 111.08M | 77.71M | 59.25M | 32.87M | 11.76K | 94.2M | 67.06M | — | — | — | — | — | — | — | — | — |
| shares | — | 1.46B | 1.24B | 1.12M | 1.02M | 1.01M | 725.13K | 564.19K | 440.02M | 242.85M | 111.08M | 77.71M | 59.25M | 32.87M | 11.76K | 5887 | — | — | — | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Showing the latest 26 of 29 periods — chart a line item for full history.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2013–FY2015: $240K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.45×
EV/EBIT
—
Peer median 11.37×
P/E (TTM)
—
Peer median 5.37×
Peer medians compare against the 314 similar-size Biotechnology companies (of 522 listed).